Remote Therapeutic Monitoring (RTM) is no longer the “new revenue opportunity.” Heading into 2026, CMS has made it clear: RTM is here to stay—but only for practices that can demonstrate medical necessity, clinical intent, and defensible documentation. While new federal rules expand billing flexibility, they also raise expectations. RTM is evolving into a clinical accountability framework where structured workflows and compliance separate sustainable programs from fragile ones